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develop while clarity on methods to evaluate the cognitive impact of this technol-
ogy have lagged. The steps we present provide a standardized system for ensuring 
that ePROs measure what is intended and the risk to research data is minimized.
PRM135
Risks, iMPacts, and Mitigation of Missing ePRo data on clinical 
tRials
Holzbaur E., Ross J.
Almac Clinical Technologies, Souderton, PA, USA
Objectives: Although missing and incomplete responses in ePROs can be mini-
mized through risk assessment and mitigation plans, missing data can have varying 
implications on clinical trials. This conceptual paper assesses the impact of missing 
ePRO data to the trial, taking into account the phase of the trial and intended use 
of the data. MethOds: Common uses for data gathered via ePRO instruments and 
diaries are reviewed. An assessment of the impact of different levels of missing 
data and associated risks with analyzing data is also performed. Results: Data 
gathered via ePRO are frequently used to support primary/secondary trial endpoints. 
They are also commonly used for exploratory purposes, allowing sponsors to gather 
preliminary information to guide the planning of future trials. Types of data col-
lected may include study medication usage for study drug reconciliation reasons, 
symptom presence or severity to determine eligibility for trial participation, and 
responses over time to indicate improvement or worsening of the symptom/disease. 
Each data use is assessed for risks to the analyzability of the data associated with 
different levels of missing data. For example, in projects with ePRO responses used 
to support primary/secondary endpoints overall project risk is low when compliance 
rates are high (e.g. 90-100%). As compliance rates drop to < 80%, bias introduced in 
the results increases, quality of the data decreases, and risks that the data may 
not be able to be used in the analysis rises. Impacts could include a need to recruit 
additional patients or that the trial may need to be re-run. cOnclusiOns: Impacts 
of missing data on clinical trial analysis vary depending on the intended use of the 
data. It is important to understand the impact of missing data to the project so that 
an appropriate plan can be decided upon and included in the protocol.
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Methodological and oPeRational consideRations in conducting 
RetRosPective Medical chaRt Review studies in hosPitals and 
Medical centeRs in eMeRging MaRkets
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Objectives: Retrospective medical chart reviews are an increasingly valuable 
source of data for clinical, treatment patterns, and outcomes research, particularly 
in emerging markets where availability of databases for secondary analysis is lim-
ited. This abstract aims to describe methodological and operational considerations 
that sponsors and researchers should be aware of prior to and during the undertak-
ing of chart review studies in these markets. MethOds: Key considerations for 
executing chart review studies in hospitals and major medical centers from study 
conception through the completion and quality review of data collection were iden-
tified and summarized. Results: After identification of research objectives and 
target countries/markets for research, thoughtful consideration of site selection 
(single or multi-site/country, local investigator interest and availability), data avail-
ability (nature, comprehensiveness, and quality of existing medical records), and 
patient selection (sampling design, specificity of inclusion/exclusion criteria) form 
the basis for implementing a successful chart review. Study design steps may be 
taken to optimize performance, for example: careful consideration of how inclusion/ 
exclusion criteria will impact patient recruitment given the rarity of the study condi-
tion (data on this may be limited); assessing feasibility of data collection instrument 
completion via piloting and prior local experience; standardization of terms and 
definitions to ensure cross-site comparability. Additional operational considerations 
include meeting varied requirements for obtaining national/state and local ethics 
approval in multi-country studies, use of electronic data capture given variation in 
information technology infrastructure across study sites, and impact of workday/
cultural traditions on recruitment/ timelines. cOnclusiOns: To maximize the 
opportunity for successful medical chart review studies in emerging markets, review 
and assessment of operational feasibilities in the target research areas, appropriate 
tailoring of study objectives, engagement of local investigators and site staff, and 
continuous oversight of data collection and quality control processes are essential.
PRM138
a fRaMewoRk foR analysing tReatMent sequences: incoRPoRating 
tiMe dePendent tRansitions thRough PaRtitioned suRvival analysis
Briggs A.1, Sidhu M.2, Baker T.2
1University of Glasgow, Glasgow, UK, 2ICON, Morristown, NJ, USA
It is often the case that cost-effectiveness models need to consider the sequence 
of treatments in a treatment algorithm. Since traditional state transition Markov 
models have an inherent memoryless property, time dependency in time to event 
analysis cannot be incorporated in this modelling framework. This has been used 
as a rationale for moving to individual level simulation models to handle treatment 
sequences. However, individual simulation models increase the computational bur-
den of a model, particularly when it comes to undertaking real-time probabilistic 
sensitivity analysis to characterize uncertainty. Therefore, adifferent approach to 
modeling treatment sequencing should be examined. In this paper, we discuss a 
novel approach to analyzing sequencing models that allow time dependency in the 
time to event analysis within a cohort model framework,thus avoiding the disad-
vantages of resorting to individual simulation. Typically parametric survival models 
can be used to characterize time to event. This may be time to overall survival or 
time to progression in cancer modelling, or time to treatment failure / treatment 
switching in oncology. We illustrate the approach using parametricWeibull models, 
although in principle any parametric survival model could be used. We show how 
sources may be integrated in order implement prospective observational research 
studies that answer complex research questions.
ReseaRch on Methods – conceptual Papers
PRM132
what aRe the Roles of health econoMic Models in PRoduct 
develoPMent?
Wu E., Davies G.M., Koglin J., Cook J.
Merck, North Wales, PA, USA
Objectives: Health economic models are widely used for drug evaluation during 
the post-approval and reimbursement process. However, similar models can also 
be used to inform objectives, decisions and designs earlier in the drug develop-
ment process with the idea to optimize the potential future value to payers. This 
project assesses how an economic heart failure (HF) model can facilitate the deci-
sion making process during the early stages of drug development. MethOds: A 
discrete event simulation is developed to track the events associated with disease 
progression of HF patients over 5 years. Patients are initially categorized into one 
of three health states based on their HF status: in-hospital, 30 days post-discharge 
and > 30 days post-discharge. To capture movement in the model, the time to hos-
pital discharge, re-hospitalization and death are generated based on each patient’s 
current health state and the event rates taken from available literature. The model 
is used to identify baseline levels of risk, a range of potential prices or the required 
drug efficacy that the drug candidate needs to meet in order to be cost-effective 
compared to standard care. Results: By way of illustration, we considered a patient 
with baseline mortality risk of 0.1% and a 0.2% readmission rate per day. If treatment 
costing $1 /day is provided to patients outside of hospital, a mortality reduction of at 
least 12% is needed to meet a $25,000/QALY threshold. For a higher risk population, 
the treatment can remain cost-effective at either a higher price or lower clinical 
efficacy. cOnclusiOns: This study demonstrates that health economic models 
are useful to determine the acceptable ranges of baseline risk, efficacy, and price to 
assess the potential value of future drug candidates.
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the Role of statistical validation?
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Objectives: To explore the appropriate use of surrogates within an economic 
modeling framework, compared to the statistical approaches of validating sur-
rogates. MethOds: We reviewed the statistical literature on validating surrogate 
endpoints. Published statistical approached to validating surrogate endpoints 
include those described by Prentice and Buyse. We explore the use of these sta-
tistical approaches to validation in the context of health economic models where 
surrogates are used (a) predict final outcomes, and (b) as endpoints for stopping 
rules and patient access schemes. Results: Given regulatory trials powered on 
surrogate endpoints, economic modeling often requires the use of surrogate end-
points to estimate the impact of treatment on final health outcomes of interest to 
reimbursement agencies. This requirement occurs even when there is no statisti-
cal validation of the surrogacy relationship, or when the surrogate fails a formal 
statistical validation. As a consequence we argue that the appropriate focus for 
economic modeling is on the appropriate propagation of uncertainty in the esti-
mates of the effect of the surrogate on final health outcome and the avoidance of 
bias due to multiple testing rather than the formal testing of validity. This includes 
the use of stopping rules that are designed to improve cost-effectiveness estimates 
for patient access. cOnclusiOns: The approach to surrogacy in reimbursement 
is necessarily different to that in a regulatory environment. We outline a general 
estimation approach based on appropriately characterizing uncertainty in the sur-
rogacy relationship rather than the formal statistical testing of surrogate validity 
as the appropriate focus of reimbursement models.
PRM134
standaRdizing cRiteRia foR cognitive assessMent of PaPeR-to-
electRonic equivalence of PRos
Martin M.L., McCarrier K.P.
Health Research Associates, Inc., Seattle, WA, USA
AiMs: Use of electronically administered outcome measures is increasing in clinical 
trial data collection. The 2009 ISPOR ePRO Task Force Report recommends cogni-
tive assessment as sufficient evidence of equivalence when only minor changes 
have been made to the measure. No consensus exists, however, for how cognitive 
assessment results should be evaluated to determine if equivalence has been estab-
lished. MethOds: Existing literature around equivalence assessment for PROs was 
combined with firsthand experience in conducting over 500 cognitive interviews 
aimed at assessing paper and electronic equivalence of 55 different PRO instru-
ments. Using these two resources, we developed suggested criteria to cognitively 
assess equivalence between the two modes, and present a practical process for 
meeting these criteria. Results: The criteria for determining equivalence between 
paper and ePRO formats should focus primarily on whether or not the ePRO is likely 
to produce data substantially different if administered via one method versus the 
other. To determine whether such a risk to ePRO data exists, we propose a three-
step process for interpreting cognitive interview responses. 1) Determine whether a 
patient perceives a cognitive difference between paper PRO and ePRO, and whether 
that difference represents a variation in the understanding of the item or simply a 
recognition of different appearance; 2) Determine whether any difference in patient 
understanding has a meaningful impact on their response to the item, and 3) deter-
mine whether or not that difference presents a significant risk to the data that 
justifies modification of the ePRO. cOnclusiOns: In the years since the ISPOR ePRO 
Task Force issued their recommendations, data capture technology has continued to 
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This method uses the life table data directly to derive an empiric distribution of 
death times. Additionally, parametric survival analysis may be used to fit life table 
data. This method may be more flexible, avoiding the need to look up mortality 
hazards directly from life tables, requiring fewer parameters, and possibly sav-
ing computation time. Typically, this method is carried out by linearizing specific 
parametric survival distributions and using regression analysis on data from the 
life table to obtain estimates for the parameters of the distribution. Although this 
type of analysis is fairly straightforward, the estimates of the uncertainty around 
the parameters are inaccurate. A new method of obtaining these parameters, which 
involves simulating individual death times from the life table data and using maxi-
mum likelihood estimation to obtain the needed parameters, may be considered 
when modeling all-cause mortality. Utilizing the number of individuals at risk, this 
method may provide more accurate estimates of parameters and their uncertainty. 
The implementation, appropriateness, challenges, advantages and disadvantages 
of these three techniques when modeling all-cause mortality in health economic 
models will be discussed.
PRM142
Joint bayesian netwoRk Meta-analysis foR event counts and 
hazaRds – coMPaRison of Methods and iMPleMentations
Schmidt H., Nehmiz G.
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
Networks of treatments summarize all available information about the relative 
effectiveness of several treatments, also if both direct and indirect evidence needs to 
be combined[1]. For clinical trials with survival results, some will have been reported 
based on numbers of patients with event, and some based on the hazard ratio. A 
common scale for mapping the observed effects has been proposed[2]. Treatment 
contrasts would then be estimated through Bayesian methodology based on Markov 
Chain Monte Carlo (MCMC) simulation. Similar problems arise for trials with binary 
outcome. We investigate one example from pulmology and compare two imple-
mentations of the MCMC method, WinBUGS and SAS® PROC MCMC. Moreover, we 
investigate a deterministic-numerical approximation to the distribution of treat-
ment contrasts, the integrated nested Laplace approximation (INLA) method. Of 
particular interest here is the goodness of the approximation, as the example 
dataset includes only small numbers of trials, patients and events. We show how 
to condense graphically the complex pattern of multiple treatment comparisons. 
We conclude with remarks on model selection, goodness-of-fit and the Deviance 
Information Criterion (DIC).
PRM143
PRactical issues when conducting netwoRk Meta-analyses with a 
liMited nuMbeR of studies
Odom D., Chirila C., Sherrill B., Wang J.
RTI Health Solutions, Research Triangle Park, NC, USA
Objectives: Meta-analysis is being conducted extensively in part due to require-
ments from health care decision-making agencies. Meta-analysis techniques con-
tinue to develop, and software now exists to model networks using Bayesian or 
frequentist approaches with study effects treated as fixed or random. The non-
model based anchored indirect-treatment comparison (AIC) method is also suit-
able for making pairwise treatment comparisons. However, practical issues emerge 
particularly when the network is comprised of a limited number of studies. Of 
special interest is the situation where a star network contains only one trial for 
a given treatment comparison. Our goal was to investigate the performance and 
interpretation of different meta-analysis methods when few studies are availa-
ble. MethOds: Example star networks anchored by placebo were created for binary 
endpoints with varying proportions and sample sizes. Generalized linear mixed 
models were fitted using PROC GLIMMIX in SAS with a random study effect. Results 
were compared to the AIC method as well as analogous Bayesian models using 
WinBUGS. Results: Estimated odds ratios were examined to identify patterns 
among methods. If placebo effects were largely different across individual trials, 
differences between methods varied depending on effect sizes and sample sizes. If 
placebo effects were similar, the frequentist random-effects model was not able to 
estimate a random study effect and it was reduced to a fixed-effect model (similar 
to the AIC). cOnclusiOns: The limitations of conducting a meta-analysis with a 
small number of trials should be understood regardless of the methodology used. In 
the special case of a star network with only one trial per treatment comparison, the 
differences between methods depend on the underlying evidence. The implications 
for interpretation will be discussed.
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exPloRing the iMPact of stRuctuRal unceRtainty in PaRtitioned 
suRvival Models foR oncology
Beca J.1, Hoch J.S.2
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Objectives: Economic evaluations in oncology built using partitioned survival 
analysis do not permit analysis of the post-progression period separately from the 
progression-free period. Moreover, when the outcomes are not complete at the 
time of the analysis, the benefits experienced by patients in the clinical trial used 
to inform the model are assumed to continue for the duration of the model due 
to extrapolation of the trial data using one set of parametric curves. The objective 
of this study is to present and contrast possible methods to address the struc-
tural uncertainty in the incremental effects and the cost-effectiveness estimates 
derived from partitioned survival models. MethOds: Options for addressing the 
long-term benefits in partitioned survival models are explored using a hypotheti-
cal economic model with three states (progression-free, progressed disease, and 
death). The methods include the standard approach of projecting treatment group 
PFS and OS outcomes using parametric survival curves, using time-varying hazard 
ratios to modify the relative benefits between treatments, calculating and modi-
fying treatment-related Markov probabilities following progression in the cohort, 
the framework is flexible enough to capture treatment effects that vary by line of 
therapy, and we demonstrate how appropriate discounting to allow for differential 
timing can still be made. We believe that the framework illustrated in this paper 
has wide applicability to sequencing models in many disease areas, most nota-
bly oncology and rheumatology where such sequencing models are common. We 
demonstrate the flexibility of the approach and show how time dependency can be 
incorporated at any sequence of the model without having to resort to individual 
patient simualation.
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a coMPRehensive econoMic and PRicing Modeling fRaMewoRk foR 
undeRstanding oRPhan dRug develoPMent
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Rare diseases provide a perplexing problem for reimbursement agencies. Orphan 
drug development is often incentivized by government entities. Despite these 
incentives, reimbursement at a viable level is not assured, and recent efforts by 
reimbursement bodies are changing the reimbursement paradigm substantially. 
Value-based pricing agreements, which link the price of the drug to the value 
achieved, is one such effort. However, demonstrating value for an orphan drug 
remains challenging. To better understand the potential value and therefore pricing 
of orphan drugs, we developed a comprehensive model to evaluate the pricing, eco-
nomics, reimbursement, and market strategy (PERMS) specifically for these drugs. 
The interactive simulation model was developed to combine evidence on develop-
ment costs, cost-effectiveness, treatment pathways, improvements in quality of 
life, and market share. The PERMS model was designed to evolve alongside the 
drug development process, incorporating new parameters and data as they become 
known. Extensive sensitivity analyses are performed to highlight the substantial 
uncertainty in disease prevalence and costs of the diseases. An interactive inter-
face is developed for users to examine how changes in model input values affect 
outcomes of interest. In this presentation, we will describe the primary elements 
of the PERMS model, demonstrate how the results may vary across subpopulations 
and illustrate the potential value of new drugs. Concepts will be illustrated through 
the use of real-world examples such as graft-versus-host disease (GVHD); a major 
complication of stem cell or bone marrow transplantation that has significant prog-
nostic implications in the setting of a rare resource. This presentation will illustrate 
how a holistic view through simulation modeling can be useful and informative for 
understanding disease burden and potential reimbursement levels and making a 
decision to proceed to the next phase of drug development.
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concePtual Model develoPMent and PRos foR non-diabetic 
PeRiPheRal neuRoPathic Pain
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Objectives: To demonstrate how a conceptual model of symptoms of non-diabetic 
peripheral neuropathic pain, impact on quality of life and tolerability of treatments 
helps to select patient reported outcomes (PROs) in clinical trials. To show that 
the selected PROs measure what is expected. MethOds: A literature review and 
interviews with 4 clinical experts were conducted to identify the PRO measurement 
concepts related to symptoms and impacts of highest importance and relevance 
to non-diabetic peripheral neuropathic pain patients. The mechanism of action 
of treatments available and in development were also included in the conceptual 
model. Based on this information, available instruments were evaluated to assess 
if measures focusing on emerging, central concepts were available and of relevance 
to a planned Phase IV study. Results: Based on the literature review and expert 
interviews, pain was the predominant symptom concept. The most predominant 
impact concepts were difficulty with sleep quantity and quality. Available treat-
ments suggested detrimental impact on cognition and local treatment-related 
pain. Instruments that seem to measure the central concepts were numerical pain 
rating scale scale (NPRS), MOS-Sleep and MOS-Cog. Furthermore the Treatment 
Satisfaction Questionnaire for Medication (TSQM) was assessed in order to be able 
to measure treatment satisfaction comparing different medications Results of the 
chosen PROs included in a Phase IV study with patients with non-diabetic peripheral 
neuropathic pain seem to show that they are able to measure the concepts they 
were selected to assess. cOnclusiOns: The FDA PRO Guidance states that meas-
ures should be conceptually valid as they relate to the disease being studied, meet 
a threshold of psychometric soundness, and be relevant to patients. This research 
represents an important step toward establishing the PROs that could be used in 
studies with patients with non-diabetic peripheral neuropathic pain.
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Modeling all-cause MoRtality in health econoMic Models
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The estimation of life-years is an important component of many health economic 
models and this outcome is often required by health technology assessment agen-
cies in the evaluation of health care technologies. Life-years are often obtained 
by adjusting the country-, age-, and gender-specific all-cause mortality, which 
considers all deaths in a population regardless of the cause, to account for addi-
tional deaths due to a specific disease (i.e., the disease-specific mortality). Properly 
modeling all-cause mortality and knowing the uncertainty associated with the 
estimates (if estimated) is therefore an important step in building a health eco-
nomic model. The report of the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) Modeling Good Research Practices Task Force recom-
mends modeling all-cause mortality non-parametrically based on life table data. 
